过敏性鼻炎治疗药物的现状与展望

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Allergic rhinitis (AR) is a chronic respiratory disease mediated by IgE，and it is also a common global respiratory multiple disease. It has the characteristics of high incidence，high recurrence rate and difficult to cure，which has a serious impact on the quality of life of patients，so the search for effective anti-AR drugs has become the focus of medical research. With the in-depth study of the pathogenesis of AR，Western medicine therapy represented by antihistamines and hormone drugs，targeted drugs represented by anti-IgE monoclonal antibody，and immunotherapy represented by lymphatic immunotherapy and epidermal immunotherapy continue to emerge，and some drugs have achieved gratifying results. In addition，traditional Chinese medicine，as a substitute and supplement，has shown a good application prospect in the treatment of AR. This paper summarizes the current situation of drug treatment of AR，combs the shortcomings of existing therapeutic drugs，and looks forward to the possible breakthrough direction of treatment in the future，in order to provide new ideas and reference for follow-up drug development.

Key words： Allergic rhinitis Pharmacotherapy Traditional Chinese medicine therapy Review

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Pan-feng
	ZHANG Shan-hua
	QIU Xiao-hua
	HOU Rong
	ZHU Chong-mei
	CHENG Ru-bin

Cite this article:

CHENG Pan-feng,ZHANG Shan-hua,QIU Xiao-hua, et al. Current status and prospect of pharmacotherapy for allergic rhinitis[J]. 中国当代医药, 2020, 27(18): 21-24.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I18/21

［1］	Mims JW.Epidemiology of allergic rhinitis［J］.Int Forum Allergy Rhinol，2014，4 Suppl 2：S18-S20.
［2］	洪元庚.过敏性鼻炎的病因、治疗现状与影响因素［J］.中国医学创新，2018，15（11）：144-148.
［3］	Brozek JL，Bousquet J，Agache I，et al.Allergic Rhinitis and its Impact on Asthma （ARIA） guidelines-2016 revision［J］.J Allergy Clin Immunol，2017，140（4）：950-958.
［4］	Okubo K，Kurono Y，Fujieda S，et al.Japanese Guideline for Allergic Rhinitis 2014［J］.Allergol Int，2014，63（3）：357-375.
［5］	李丽莎，关凯，崔乐，等.单药加倍或多药联合治疗变应性鼻炎效果比较［J］.临床耳鼻咽喉头颈外科杂志，2018，32（1）：27-32.
［6］	Seresirikachorn K，Chitsuthipakorn，Kanjanawasee D，et al.Leukotriene receptor antagonist addition to H1-antihistamine is effective for treating allergic rhinitis：a systematic review and Meta-analysis［J］.Am J Rhinol Allergy，2019，33（5）：591-600.
［7］	Heffler E，Brussino L，Del GS，et al.New drugs in earlystage clinical trials for allergic rhinitis［J］.Expert Opin Investig Drugs，2019，28（3）：267-273.
［8］	Pozzoli M，Traini D，Young PM，et al.Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery［J］.Drug Dev Ind Pharm，2017，43（9）：1510-1518.
［9］	刘英，叶小静，赵春丽，等.联合用药治疗季节性变应性鼻炎的疗效观察［J］.临床耳鼻咽喉头颈外科杂志，2016，30（13）：1049-1052.
［10］	黄慧贞.氯雷他定联合糖皮质激素鼻喷雾剂对过敏性鼻炎合并哮喘患儿症状和峰值呼气流速的影响［J］.中国合理用药探索，2019，16（5）：58-61.
［11］	Okubo K，Kurono Y，Ichimura K，et al.Japanese Guideline for Allergic Rhinitis 2017［J］.Allergol Int，2017，66（2）：205-219.
［12］	Stokes JR，Casale TB.The use of anti-IgE therapy beyond allergic asthma［J］.J Allergy Clin Immunol Pract，2015，3（2）：162-166.
［13］	Chu SY，Horton HM，Pong E，et al.Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody［J］.J Allergy Clin Immunol，2012，129（4）：1102-1115.
［14］	Gomez G.Current strategies to inhibit high affinity FcεRImediated signaling for the treatment of allergic disease［J］.Front Immunol，2019，10：175.
［15］	Kim YY，Je IG，Kim MJ，et al.2-Hydroxy-3-methoxybenzoic acid attenuates mast cell-mediated allergic reaction in mice via modulation of the FcεRI signaling pathway［J］.Acta Pharmacol Sin，2017，38（1）：90-99.
［16］	Eggel A，Baumann MJ，Amstutz P，et al.DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage［J］.J Mol Biol，2009，393（3）：598-607.
［20］	Vadlamudi A，Shaker M.New developments in allergen immunotherapy［J］.Curr Opin Pediatr，2015，27（5）：649-655.
［24］	侯瑞蕊，邵玉锋，杨云峰，等.三九增免贴联合临方炮制膏方干预脾肾阳虚型季节性过敏性鼻炎的疗效［J］.广东医学，2017，38（17）：2715-2717.
［25］	黄南，李文静，赵炎，等.升阳益肾汤对肺肾阳虚型过敏性鼻炎患者免疫球蛋白lgE，lgM，lgA 及淋巴细胞表达的影响［J］.世界中医药，2019，14（7）：1771-1774，1779.
［17］	Wang Z，Tan F.The blockade of PD-1/PD-L1 pathway promotes the apoptosis of CD19 CD25 Bregs and suppresses the secretion of IL-10 in patients with allergic rhinitis［J］.Scand J Immunol，2019，47：e12836.
［18］	Zhu XW，Cong JA，Yang B，et al.Association analysis of high-mobility group box-1 protein 1 （HMGB1）/toll-like receptor（TLR）4 with nasal interleukins in allergic rhinitis patients［J］.Cytokine，2019，126：154 880.
［19］	Weinstein SF，Katial R，Jayawardena S，et al.Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma［J］.J Allergy Clin Immunol，2018，142（1）：171-177.
［21］	Hylander T，Larsson O，Petersson-Westin U，et al.Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis：a double-blind placebo-controlled trial［J］.Respir Res，2016，17：10.
［22］	Senti G，Von Moos S，Tay F，et al.Determinants of efficacy and safety in epicutaneous allergen immunotherapy：summary of three clinical trials［J］.Allergy，2015，70（6）：707-710.
［23］	Okubo K，Uchida E，Terahara T，et al.Efficacy and safety of emedastine patch，a novel transdermal drug delivery system for allergic rhinitis：Phase Ⅲ，multicenter，randomized，double-blinded，placebo-controlled，parallel-group comparative study in patients with seasonal allergic rhinitis［J］.Allergol Int，2018，67（3）：371-379.
［26］	Piao CH，Song CH，Lee EJ，et al.Saikosaponin A ameliorates nasal inflammation by suppressing IL-6/ROR-γt/STAT3/IL-17/NF-κB pathway in OVA-induced allergic rhinitis［J］.Chem Biol Interact，2019，315：108 874.
［27］	Lv C，Zhang Y，Shen L.Preliminary clinical effect evaluation of resveratrol in adults with allergic rhinitis［J］.Int Arch Allergy Immunol，2018，175（4）：231-236.